Cipla News and Updates

Name: Latest research reports of Cipla Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Cipla from all sources in a single place.

Cipla Ltd.

23 Dec 2025

1520.30

0.58%

CIPLA LTD

Hold: Cipla Ltd.

Recommendation Target

Geojit BNP Paribas

Cipla Ltd delivered a steady Q2FY26 performance, supported by strong branded generics in India and continued leadership in its US respiratory business (albuterol MDI). The company's strategic focus on high-growth therapies such as obesity and diabetes (exclusive launch of Tirzepatide Yurpeak in India) underpins its long-term growth potential. However, near-term challenges remain, including the anticipated revenue erosion from the Revlimid cliff, increased R&D intensity weighing on margins, and execution risk related to timely approvals, which could limit earnings visibility and margin recovery in the medium term, thereby warranting a more...

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla Ltd.

22 Dec 2025

1520.30

0.58%

Cipla launches inhaled insulin', a needle-free alternative for people with diabetes

Business Line

Cipla Ltd.'s price crossed above 200Day SMA today

Cipla Launches Inhalable Insulin For Diabetes Care

NDTV Profit | 22 Dec 2025 1 more

Cipla Ltd.

19 Dec 2025

1520.30

0.58%

Cipla to exclusively market and distribute five Pfizer brands in India

Business Standard

Cipla will exclusively market five Pfizer brands in India, adding 400-430 crore of established acute therapies to its portfolio without manufacturing risk

Cipla Ltd.'s price crossed above 200Day SMA today

Cipla ties up with Pfizer for exclusive marketing of four brands

livemint | 19 Dec 2025

Cipla Ltd.

10 Dec 2025

1520.30

0.58%

Cipla Launches Drug For Obesity, Diabetes

NDTV Profit

Cipla has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus.

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla Ltd.

03 Dec 2025, 07:29PM

1520.30

0.58%

Cipla, Stempeutics launch stem cell therapy for knee osteoarthritis

Business Standard

Approved by the Drug Controller General of India (DCGI), the treatment offers to slow disease progression and promote cartilage maintenance for patients with Grade II and III knee OA

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla launches Ciplostem cell therapy for Knee Osteoarthritis in India

Business Line | 03 Dec 2025, 07:02PM

Cipla Ltd.

28 Nov 2025

1520.30

0.58%

Cipla opens lung centre in Delhi

Business Line

Cipla launches a Breathefree Lung Wellness Center in Delhi to enhance lung diagnostics amid rising respiratory diseases and air pollution.

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla launches India's first integrated lung diagnostics, wellness centre

Business Standard | 28 Nov 2025

Cipla Ltd.

10 Nov 2025

1520.30

0.58%

Novo Nordisk inks collaboration with Emcure, to sell its weightloss and diabetes drug Wegovy

Business Line

The announcement comes just weeks after US company Eli Lilly announced its agreement with Cipla to sell tirzepatide in India,

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla Ltd.

04 Nov 2025, 12:00AM

1520.30

0.58%

Growth outlook intact despite near-term headwinds

Accumulate: Cipla Ltd.

Target

Deven Choksey

Cipla’s near-to-medium term outlook remains positive, underpinned by strong execution in domestic formulations and a visible ramp-up in complex generics and biosimilars in the U.S. market.